IP Library Granted Patent US 10,472,611
Granted Patent B2
US 10,472,611 · App. 16/402,175 · Granted Nov 12, 2019

Methods and products for transfecting cells

Inventors: Matthew Angel (Cambridge, MA); Christopher Rohde (Cambridge, MA)
Assignee: Factor Bioscience Inc.
C12N5/0696A61K35/28C08K5/5399C12N5/0647C12N5/0657C12N9/16C12N9/22C12N15/87C12N15/907C12P21/00C12Y301/21H01L31/048A61K2035/124C08G77/08C12N2500/25C12N2500/44C12N2501/115C12N2501/155C12N2501/165C12N2501/2303C12N2501/26C12N2501/91C12N2501/998C12N2506/09C12N2800/80Y02E10/50
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,472,611
App. No.
16/402,175
Granted
Nov 12, 2019
Kind
B2
Abstract

The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

Claims (32)

1. A method for producing a gene-edited, reprogrammed cell, comprising:

(a) providing a differentiated cell;

(b) culturing the differentiated cell; and

(c) transfecting the differentiated cell with one or more synthetic RNA molecules,

wherein the one or more synthetic RNA molecules include:

(i) at least one RNA molecule encoding one or more reprogramming factors, and

(ii) at least one RNA molecule encoding one or more gene-editing proteins;

wherein the transfecting results in the cell expressing the one or more reprogramming factors and the one or more gene editing proteins to result in a gene-edited, reprogrammed cell;

wherein step (c) is performed without using irradiated human neonatal fibroblast feeder cells and occurs in the presence of a medium containing ingredients that support reprogramming of the cell to a less differentiated state.

2. The method of claim 1 , wherein the differentiated cell is derived from a biopsy.

3. The method of claim 1 , wherein the differentiated cell is a human skin cell.

4. The method of claim 1 , further comprising contacting the differentiated cell with at least one of poly-L-lysine, poly-L-ornithine, RGD peptide, fibronectin, vitronectin, collagen, and laminin.

5. The method of claim 1 , wherein the medium is substantially free of immunosuppressants.

6. The method of claim 1 , wherein the one or more synthetic RNA molecules comprise at least one of a pseudouridine or a 5-methylcytidine residue.

7. The method of claim 1 , wherein the one or more synthetic RNA molecules further comprise one or more of a 5′-cap, a 5′-cap 1 structure, and a 3′-poly(A) tail.

8. The method of claim 1 , wherein the one or more reprogramming factor(s) are selected from Oct4 protein, Sox2 protein, Klf4 protein, c-Myc protein, 1-Myc protein, Tert protein, Nanog protein, and Lin28 protein.

9. A method for producing a gene-edited, reprogrammed cell, comprising:

(a) providing a non-pluripotent cell;

(b) culturing the non-pluripotent cell; and

(c) transfecting the non-pluripotent cell with one or more synthetic RNA molecules,

wherein the one or more synthetic RNA molecules include:

(i) at least one RNA molecule encoding one or more reprogramming factors, and

(ii) at least one RNA molecule encoding one or more gene-editing proteins;

wherein the transfecting results in the cell expressing the one or more reprogramming factors and the one or more gene editing proteins to result in a gene-edited, reprogrammed cell;

wherein step (c) is performed without using irradiated human neonatal fibroblast feeder cells and occurs in the presence of a medium containing ingredients that support reprogramming of the cell.

10. The method of claim 9 , wherein the non-pluripotent cell is derived from a biopsy.

11. The method of claim 9 , wherein the non-pluripotent cell is a human skin cell.

12. The method of claim 9 , further comprising contacting the non-pluripotent cell with at least one of poly-L-lysine, poly-L-ornithine, RGD peptide, fibronectin, vitronectin, collagen, and laminin.

13. The method of claim 9 , wherein the medium is substantially free of immunosuppressants.

14. The method of claim 9 , wherein the one or more synthetic RNA molecules comprise at least one of a pseudouridine or a 5-methylcytidine residue.

15. The method of claim 9 , wherein the one or more synthetic RNA molecules further comprise one or more of a 5′-cap, a 5′-cap 1 structure, and a 3′-poly(A) tail.

16. The method of claim 9 , wherein the one or more reprogramming factor(s) are selected from Oct4 protein, Sox2 protein, Klf4 protein, c-Myc protein, 1-Myc protein, Tert protein, Nanog protein, and Lin28 protein.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2019
From: ANGEL, MATTHEW; ROHDE, CHRISTOPHER
To: FACTOR BIOSCIENCE INC.
Reel/Frame 049130/0674 →
Continuity (9)
Continuation 15429795 · Feb 10, 2017
Continuation 15222453 · Jul 28, 2016
Continuation 14296220 · Jun 4, 2014
Continuation PCTUS2012067966 · Dec 5, 2012
Provisional Application 61566948 · Dec 5, 2011
Provisional Application 61637570 · Apr 24, 2012
Provisional Application 61664494 · Jun 26, 2012
Provisional Application 61569595 · Dec 12, 2011
Related Publication 20190270968A1 · Sep 5, 2019
Cited By (3)
US 12,227,757 US 12,391,961 US 12,559,772